Altea Therapeutics has named David Enscore, as senior vice president for product research and development.

Enscore is responsible for leading all of Altea’s pharmaceutical product research R&D activities. The company’s lead clinical products are a daily insulin skin patch for treating individuals with diabetes and a hydromorphone skin patch for the management of severe acute and chronic pain.

“David’s appointment will strengthen both our pharmaceutical development capabilities and our project management needs as we transition from a technology-based company to one developing high-value pharmaceutical products” said Altea CEO Eric Tomlinson. “The advanced skin patch technology of Altea Therapeutics holds great promise for improving drug and vaccine efficacy and safety as well as patient compliance.”

Prior to Altea, Enscore was president and head of R&D at Spherics, a drug delivery company based in Lincoln, RI. While there, he was an inventor on 24 U.S. patents in drug delivery and medical devices.

Enscore also has served as VP of R&D at Focal Inc., where he was responsible for the development of two surgical sealant products, and as executive director of transdermal product development at ALZA. While there, he managed the development of four commercial controlled release pharmaceuticals, including Nicoderm CQ.